Tamir Biotechnology Inc. (ACEL)

[Perris]

COVER STORY - ACEL'S ONCONASE
APRIL ISSUE OF DRUG DISCOVERY & DEVELOPMENT

LINK TO SUBSCRIBE TO THE ARTICLE:
http://www.dddmag.com/DDD-upcoming-issues.aspx?menuid=54
April, 2008 Issue

Discovery
COVER STORY
Beating Drug Resistance: Cancer Drugs
Drug resistance is a major impediment to successful strategies for cancer therapy. New tools for gene expression profiling are now converging with the world of small non-coding RNAs (ncRNAs). Strategies to overcome drug resistance will be reviewed generally and with respect to Onconase (ranpirnase) from Alfacell.

Data Mining
This article outlines some of the issues with safety data and describes some data mining methods that address challenges. Statistical data mining models include hierarchical generalized linear models and inside-out machine learning models. Graphical analysis and reporting also is covered.


Development
Advances in HIV Drug Development
Senior editor James Netterwald will discuss current and emerging HIV treatment modalities. Special focus will be placed on emerging HIV treatments that utilize new strategies including new targets, new drug delivery options, and combination therapies.

Insect Bioreactors
Senior editor James Netterwald will discuss how insect cells are used to product biopharmaceuticals. Types of cells, bioreactor vessels, conditions, and new drugs developed in insect bioreactors will be the described in detail.

Genomics and Proteomics
MS vs. NMR for Protein Analysis
This article will discuss the pros and cons of using NMR or MS for protein analysis. Issues such as sensitivity of these methods and how bioinformatics is used to organize data resulting from them will be addressed in the context of proteomics research.

Real-time qPCR
This article discusses how preparation of RNA can affect qPCR results. Current RNA sample prep technologies are discussed. Examples illustrate the strengths and weaknesses of each technology with regard to the effects of RNA sample prep on qPCR.

Industry Issues
Building a Better Drug: New Development Strategies
For those suffering from migraine pain, relief cannot come soon enough. TorreyPines Therapeutics’s Tezampanel has completed Phase IIb clinical trials, representing the first novel treatment option in more than a decade. The company will discuss its strategy of developing versatile product candidates capable of treating a number of different diseases and disorders.

Departments
Technology Advances
Contributing Editor Mike May will discuss advances in Chemistry.

Policy & Projections
Contributing Editor Ted Agres will examine current issues before Congress and pending FDA regulations.